- Jon Serbousek to succeed Brad Mason as President and Chief Executive Officer on November 1, 2019
- Net sales of $115.9 million, an increase of 3.9% compared to prior year and 5.0% on a constant currency basis
- Biologics products net sales increased 14.2% and now has #1 market share position within its segment1
- $500,000 in US M6-C cervical disc sales since June 1
- Company reiterates full year 2019 guidance
LEWISVILLE, Texas–(BUSINESS WIRE)–Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the second quarter ended June 30, 2019. Net sales were $115.9 million, loss per share (“EPS”) was ($0.03) and adjusted EPS was $0.28.
“First and foremost, I am very pleased to announce that Jon Serbousek, a highly regarded and seasoned orthopedic and spine executive, has joined the Orthofix executive team. For more details, please see the press release we will issue today on the announcement,” said Brad Mason, Orthofix President and Chief Executive Officer. “Regarding the second quarter results, net sales were in line with our expectations, led by another quarter of outstanding performance in our Biologics products and notably, as reported by SmartTRAK®, Orthofix now has the number one market share position in the U.S. cellular allograft segment.”
Mason continued, “I am also happy to report that the launch of the M6-C™ cervical disc in the U.S. is going very well and ahead of plan. With fewer than two dozen surgeons implanting discs to date, we’ve generated $500,000 in sales since June 1st and expect to end the year with more than 150 surgeons trained. This gives us great confidence that we will meet or exceed our sales expectations for 2019 and exit the year on a strong growth trajectory.”
Financial Results Overview
The following table provides net sales by major product category by reporting segment:
|
|
|
Three Months Ended June 30, |
|
|||||||||||||
|
(Unaudited, U.S. Dollars, in thousands) |
|
2019 |
|
|
2018 |
|
|
Change |
|
|
Constant Currency Change |
|
||||
|
Bone Growth Therapies |
|
$ |
50,109 |
|
|
$ |
48,211 |
|
|
|
3.9 |
% |
|
|
3.9 |
% |
|
Spinal Implants |
|
|
23,226 |
|
|
|
23,880 |
|
|
|
(2.7 |
%) |
|
|
(2.0 |
%) |
|
Biologics |
|
|
16,744 |
|
|
|
14,668 |
|
|
|
14.2 |
% |
|
|
14.2 |
% |
|
Global Spine |
|
|
90,079 |
|
|
|
86,759 |
|
|
|
3.8 |
% |
|
|
4.0 |
% |
|
Global Extremities |
|
|
25,771 |
|
|
|
24,788 |
|
|
|
4.0 |
% |
|
|
8.5 |
% |
|
Net sales |
|
$ |
115,850 |
|
|
$ |
111,547 |
|
|
|
3.9 |
% |
|
|
5.0 |
% |
Gross profit increased $1.3 million to $90.0 million. Gross margin decreased to 77.7% compared to 79.5% in the prior year period, primarily due to higher than normal charges related to the buildup of Spinal Implants inventory to support sales growth from our new sales partners in key geographies.
Net loss was ($0.5) million, or ($0.03) per share, compared to net income of $0.9 million, or $0.05 per share in the prior year period. Adjusted net income from continuing operations was $5.5 million, or $0.28 per share, compared to adjusted net income of $8.0 million, or $0.42 per share in the prior year period.
EBITDA was $6.4 million, compared to $6.8 million in the prior year period. Adjusted EBITDA was $17.3 million, or 14.9% of net sales, compared to $22.0 million, or 19.7% of net sales, in the prior year period.
Liquidity
As of June 30, 2019, cash, cash equivalents, and restricted cash totaled $52.1 million compared to $72.2 million as of December 31, 2018. As of June 30, 2019, the Company had no outstanding indebtedness and borrowing capacity of $125 million under its existing credit facility. Cash flow from operations for the six months ended June 30, 2019 decreased $4.7 million to $8.3 million when compared to the prior year period, while free cash flow decreased $8.4 million to ($2.0) million.
2019 Outlook
For the year ending December 31, 2019, the Company expects the following results, assuming exchange rates are the same as those currently prevailing.
|
|
|
Previous 2019 Outlook |
|
|
Current 2019 Outlook |
|||||||||||||
|
(Unaudited, U.S. Dollars, in millions, except per share data) |
|
Low |
|
|
High |
|
|
Low |
|
High |
||||||||
|
Net sales |
|
$ |
472.0 |
|
|
$ |
477.0 |
|
|
$ |
472.0 |
|
1 |
|
$ |
477.0 |
|
1 |
|
Net income |
|
$ |
14.6 |
|
|
$ |
15.5 |
|
|
$ |
12.7 |
|
2 |
|
$ |
13.6 |
|
2 |
|
Adjusted EBITDA |
|
$ |
86.0 |
|
|
$ |
89.0 |
|
|
$ |
86.0 |
|
3 |
|
$ |
89.0 |
|
3 |
|
EPS |
|
$ |
0.75 |
|
|
$ |
0.80 |
|
|
$ |
0.66 |
|
4 |
|
$ |
0.70 |
|
4 |
|
Adjusted EPS |
|
$ |
1.75 |
|
|
$ |
1.82 |
|
|
$ |
1.75 |
|
5 |
|
$ |
1.82 |
|
5 |
|
1 |
Represents a year-over-year increase of 4.2% to 5.3% on a reported basis |
|
2 |
Represents a year-over-year decrease of 8.0% to 1.5% |
|
3 |
Represents a year-over-year decrease of 1.8% to a year-over-year increase of 1.6% |
|
4 |
Represents a year-over-year decrease of 8.3% to 2.8% |
|
5 |
Represents a year-over-year decrease of 2.2% to year-over-year increase of 1.7% |
Conference Call
Orthofix will host a conference call today at 4:30 PM Eastern time to discuss the Company’s financial results for the second quarter of 2019. Interested parties may access the conference call by dialing (844) 809-1992 in the U.S. and (612) 979-9886 outside the U.S., and referencing the conference ID 1534617. A replay of the call will be available for two weeks by dialing (855) 859-2056 in the U.S. and (404) 537-3406 outside the U.S., and entering the conference ID 1534617. A webcast of the conference call may be accessed by going to the Company’s website at www.orthofix.com, by clicking on the Investors link and then the Events and Presentations page.
About Orthofix
Orthofix Medical Inc. is a global medical device company focused on musculoskeletal products and therapies. The Company’s mission is to improve patients’ lives by providing superior reconstruction and regenerative musculoskeletal solutions to physicians worldwide. Headquartered in Lewisville, Texas, Orthofix’s spine and orthopedic extremities products are distributed in over 70 countries via the Company’s sales representatives and distributors. For more information, please visit www.orthofix.com.
Forward-Looking Statements
This communication contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (“the Exchange Act”), and Section 27A of the Securities Act of 1933, as amended, relating to our business and financial outlook, which are based on our current beliefs, assumptions, expectations, estimates, forecasts and projections. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “intends,” “predicts,” “potential,” or “continue” or other comparable terminology. These forward-looking statements are not guarantees of our future performance and involve risks, uncertainties, estimates and assumptions that are difficult to predict. Therefore, our actual outcomes and results may differ materially from those expressed in these forward-looking statements. You should not place undue reliance on any of these forward-looking statements. Further, any forward-looking statement speaks only as of the date hereof, unless it is specifically otherwise stated to be made as of a different date. We undertake no obligation to further update any such statement, or the risk factors described in Part I, Item 1A under the heading Risk Factors in our Form 10-K for the year ended December 31, 2018, to reflect new information, the occurrence of future events or circumstances or otherwise.
1 Per SmartTRAK Q1/19 Market Recap: OrthoBio Report, US Stem Cell segment
|
ORTHOFIX MEDICAL INC. Condensed Consolidated Statements of Operations |
||||||||||||||||
|
|
|
Three Months Ended |
|
|
Six Months Ended |
|
||||||||||
|
|
|
June 30, |
|
|
June 30, |
|
||||||||||
|
(Unaudited, U.S. Dollars, in thousands, except share and per share data) |
|
2019 |
|
|
2018 |
|
|
2019 |
|
|
2018 |
|
||||
|
Net sales |
|
$ |
115,850 |
|
|
$ |
111,547 |
|
|
$ |
224,962 |
|
|
$ |
220,256 |
|
|
Cost of sales |
|
|
25,812 |
|
|
|
22,835 |
|
|
|
49,520 |
|
|
|
46,982 |
|
|
Gross profit |
|
|
90,038 |
|
|
|
88,712 |
|
|
|
175,442 |
|
|
|
173,274 |
|
|
Sales and marketing |
|
|
56,864 |
|
|
|
51,529 |
|
|
|
110,558 |
|
|
|
101,797 |
|
|
General and administrative |
|
|
21,935 |
|
|
|
21,958 |
|
|
|
42,407 |
|
|
|
41,382 |
|
|
Research and development |
|
|
8,980 |
|
|
|
7,891 |
|
|
|
18,209 |
|
|
|
14,828 |
|
|
Acquisition-related amortization and remeasurement |
|
|
1,808 |
|
|
|
1,419 |
|
|
|
8,265 |
|
|
|
1,482 |
|
|
Operating income (loss) |
|
|
451 |
|
|
|
5,915 |
|
|
|
(3,997 |
) |
|
|
13,785 |
|
|
Interest income (expense), net |
|
|
457 |
|
|
|
(251 |
) |
|
|
200 |
|
|
|
(434 |
) |
|
Other expense, net |
|
|
(236 |
) |
|
|
(3,643 |
) |
|
|
(640 |
) |
|
|
(731 |
) |
|
Income (loss) before income taxes |
|
|
672 |
|
|
|
2,021 |
|
|
|
(4,437 |
) |
|
|
12,620 |
|
|
Income tax benefit (expense) |
|
|
(1,219 |
) |
|
|
(1,096 |
) |
|
|
4,787 |
|
|
|
(6,469 |
) |
|
Net income (loss) |
|
$ |
(547 |
) |
|
$ |
925 |
|
|
$ |
350 |
|
|
$ |
6,151 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) per common share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
$ |
(0.03 |
) |
|
$ |
0.05 |
|
|
$ |
0.02 |
|
|
$ |
0.33 |
|
|
Diluted |
|
|
(0.03 |
) |
|
|
0.05 |
|
|
|
0.02 |
|
|
|
0.32 |
|
|
Weighted average number of common shares: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
|
18,834,886 |
|
|
|
18,413,756 |
|
|
|
18,790,612 |
|
|
|
18,409,331 |
|
|
Diluted |
|
|
18,834,886 |
|
|
|
18,835,560 |
|
|
|
19,179,057 |
|
|
|
18,811,356 |
|
|
ORTHOFIX MEDICAL INC. Condensed Consolidated Balance Sheets |
||||||||
|
(U.S. Dollars, in thousands, except share data) |
|
June 30, 2019 |
|
|
December 31, 2018 |
|
||
|
|
|
(unaudited) |
|
|
|
|
|
|
|
Assets |
|
|
|
|
|
|
|
|
|
Current assets |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
52,143 |
|
|
$ |
69,623 |
|
|
Restricted cash |
|
|
— |
|
|
|
2,566 |
|
|
Trade accounts receivable, net of allowances of $4,205 and $7,463, respectively |
|
|
80,591 |
|
|
|
77,747 |
|
|
Inventories |
|
|
79,141 |
|
|
|
76,847 |
|
|
Prepaid expenses and other current assets |
|
|
20,954 |
|
|
|
17,856 |
|
|
Total current assets |
|
|
232,829 |
|
|
|
244,639 |
|
|
Property, plant and equipment, net |
|
|
64,402 |
|
|
|
42,835 |
|
|
Intangible assets, net |
|
|
55,628 |
|
|
|
51,897 |
|
|
Goodwill |
|
|
71,177 |
|
|
|
72,401 |
|
|
Deferred income taxes |
|
|
37,566 |
|
|
|
33,228 |
|
|
Other long-term assets |
|
|
27,204 |
|
|
|
21,641 |
|
|
Total assets |
|
$ |
488,806 |
|
|
$ |
466,641 |
|
|
Liabilities and shareholders’ equity |
|
|
|
|
|
|
|
|
|
Current liabilities |
|
|
|
|
|
|
|
|
|
Trade accounts payable |
|
$ |
19,523 |
|
|
$ |
17,989 |
|
|
Current portion of finance lease liability |
|
|
301 |
|
|
|
— |
|
|
Other current liabilities |
|
|
48,161 |
|
|
|
67,919 |
|
|
Total current liabilities |
|
|
67,985 |
|
|
|
85,908 |
|
|
Long-term portion of finance lease liability |
|
|
20,847 |
|
|
|
— |
|
|
Other long-term liabilities |
|
|
52,180 |
|
|
|
45,336 |
|
|
Total liabilities |
|
|
141,012 |
|
|
|
131,244 |
|
|
Contingencies |
|
|
|
|
|
|
|
|
|
Shareholders’ equity |
|
|
|
|
|
|
|
|
|
Common shares $0.10 par value; 50,000,000 shares authorized; 18,831,581 and 18,579,688 issued and outstanding as of June 30, 2019 and December 31, 2018, respectively |
|
|
1,883 |
|
|
|
1,858 |
|
|
Additional paid-in capital |
|
|
257,888 |
|
|
|
243,165 |
|
|
Retained earnings |
|
|
86,561 |
|
|
|
87,078 |
|
|
Accumulated other comprehensive income |
|
|
1,462 |
|
|
|
3,296 |
|
|
Total shareholders’ equity |
|
|
347,794 |
|
|
|
335,397 |
|
|
Total liabilities and shareholders’ equity |
|
$ |
488,806 |
|
|
$ |
466,641 |
|
ORTHOFIX MEDICAL INC.
Non-GAAP Financial Measures
The following tables present reconciliations of operating income (loss), net income (loss), EPS, and net cash from operating activities, in each case calculated in accordance with U.S. generally accepted accounting principles (“GAAP”), to, as applicable, non-GAAP financial measures, referred to as “EBITDA,” “Adjusted EBITDA,” “Adjusted net income,” “Adjusted EPS,” and “Free cash flow” that exclude items specified in the tables. A more detailed explanation of the items excluded from these non-GAAP financial measures, as well as why management believes the non-GAAP financial measures are useful to them, is included following the reconciliations.
EBITDA and Adjusted EBITDA
|
|
|
Three Months Ended June 30, 2019 |
|
|||||||||||||
|
(Unaudited, U.S. Dollars, in thousands) |
|
Global Spine |
|
|
Global Extremities |
|
|
Corporate |
|
|
Total Orthofix |
|
||||
|
Operating income (loss) |
|
$ |
12,696 |
|
|
$ |
1,353 |
|
|
$ |
(13,598 |
) |
|
$ |
451 |
|
|
Other income (expense), net |
|
|
175 |
|
|
|
71 |
|
|
|
(482 |
) |
|
|
(236 |
) |
|
Depreciation and amortization |
|
|
2,314 |
|
|
|
1,326 |
|
|
|
1,200 |
|
|
|
4,840 |
|
|
Amortization of acquired intangibles |
|
|
1,338 |
|
|
|
— |
|
|
|
— |
|
|
|
1,338 |
|
|
EBITDA |
|
$ |
16,523 |
|
|
$ |
2,750 |
|
|
$ |
(12,880 |
) |
|
$ |
6,393 |
|
|
Share-based compensation |
|
|
1,733 |
|
|
|
607 |
|
|
|
2,454 |
|
|
|
4,794 |
|
|
Foreign exchange impact |
|
|
(168 |
) |
|
|
(116 |
) |
|
|
1 |
|
|
|
(283 |
) |
|
Strategic investments |
|
|
591 |
|
|
|
— |
|
|
|
4,234 |
|
|
|
4,825 |
|
|
Acquisition-related fair value adjustments |
|
|
647 |
|
|
|
— |
|
|
|
— |
|
|
|
647 |
|
|
Loss on investment securities |
|
|
— |
|
|
|
— |
|
|
|
491 |
|
|
|
491 |
|
|
Legal judgments/settlements |
|
|
(555 |
) |
|
|
(318 |
) |
|
|
(4 |
) |
|
|
(877 |
) |
|
Succession charges |
|
|
132 |
|
|
|
— |
|
|
|
1,136 |
|
|
|
1,268 |
|
|
Adjusted EBITDA |
|
$ |
18,903 |
|
|
$ |
2,923 |
|
|
$ |
(4,568 |
) |
|
$ |
17,258 |
|
|
|
|
Six Months Ended June 30, 2019 |
|
|||||||||||||
|
(Unaudited, U.S. Dollars, in thousands) |
|
Global Spine |
|
|
Global Extremities |
|
|
Corporate |
|
|
Total Orthofix |
|
||||
|
Operating income (loss) |
|
$ |
20,426 |
|
|
$ |
358 |
|
|
$ |
(24,781 |
) |
|
$ |
(3,997 |
) |
|
Other income (expense), net |
|
|
(224 |
) |
|
|
(407 |
) |
|
|
(9 |
) |
|
|
(640 |
) |
|
Depreciation and amortization |
|
|
4,501 |
|
|
|
2,626 |
|
|
|
2,383 |
|
|
|
9,510 |
|
|
Amortization of acquired intangibles |
|
|
2,395 |
|
|
|
— |
|
|
|
— |
|
|
|
2,395 |
|
|
EBITDA |
|
$ |
27,098 |
|
|
$ |
2,577 |
|
|
$ |
(22,407 |
) |
|
$ |
7,268 |
|
|
Share-based compensation |
|
|
3,313 |
|
|
|
1,133 |
|
|
|
3,907 |
|
|
|
8,353 |
|
|
Foreign exchange impact |
|
|
225 |
|
|
|
342 |
|
|
|
23 |
|
|
|
590 |
|
|
Strategic investments |
|
|
1,249 |
|
|
|
— |
|
|
|
5,645 |
|
|
|
6,894 |
|
|
Acquisition-related fair value adjustments |
|
|
6,579 |
|
|
|
— |
|
|
|
— |
|
|
|
6,579 |
|
|
Loss on investment securities |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
Legal judgments/settlements |
|
|
(500 |
) |
|
|
(273 |
) |
|
|
21 |
|
|
|
(752 |
) |
|
Succession charges |
|
|
132 |
|
|
|
— |
|
|
|
3,868 |
|
|
|
4,000 |
|
|
Adjusted EBITDA |
|
$ |
38,096 |
|
|
$ |
3,779 |
|
|
$ |
(8,943 |
) |
|
$ |
32,932 |
|
|
|
|
Three Months Ended June 30, 2018 |
|
|||||||||||||
|
(Unaudited, U.S. Dollars, in thousands) |
|
Global Spine |
|
|
Global Extremities |
|
|
Corporate |
|
|
Total Orthofix |
|
||||
|
Operating income (loss) |
|
$ |
17,240 |
|
|
$ |
878 |
|
|
$ |
(12,203 |
) |
|
$ |
5,915 |
|
|
Other income (expense), net |
|
|
(544 |
) |
|
|
(1,675 |
) |
|
|
(1,424 |
) |
|
|
(3,643 |
) |
|
Depreciation and amortization |
|
|
2,024 |
|
|
|
1,285 |
|
|
|
935 |
|
|
|
4,244 |
|
|
Amortization of acquired intangibles |
|
|
310 |
|
|
|
— |
|
|
|
— |
|
|
|
310 |
|
|
EBITDA |
|
$ |
19,030 |
|
|
$ |
488 |
|
|
$ |
(12,692 |
) |
|
$ |
6,826 |
|
|
Share-based compensation |
|
|
1,836 |
|
|
|
613 |
|
|
|
2,766 |
|
|
|
5,215 |
|
|
Foreign exchange impact |
|
|
456 |
|
|
|
1,626 |
|
|
|
1,173 |
|
|
|
3,255 |
|
|
Strategic investments |
|
|
812 |
|
|
|
— |
|
|
|
3,837 |
|
|
|
4,649 |
|
|
Acquisition-related fair value adjustments |
|
|
1,473 |
|
|
|
— |
|
|
|
— |
|
|
|
1,473 |
|
|
Loss on investment securities |
|
|
— |
|
|
|
— |
|
|
|
230 |
|
|
|
230 |
|
|
Legal judgments/settlements |
|
|
212 |
|
|
|
87 |
|
|
|
75 |
|
|
|
374 |
|
|
Succession charges |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
Adjusted EBITDA |
|
$ |
23,819 |
|
|
$ |
2,814 |
|
|
$ |
(4,611 |
) |
|
$ |
22,022 |
|
|
|
|
Six Months Ended June 30, 2018 |
|
|||||||||||||
|
(Unaudited, U.S. Dollars, in thousands) |
|
Global Spine |
|
|
Global Extremities |
|
|
Corporate |
|
|
Total Orthofix |
|
||||
|
Operating income (loss) |
|
$ |
34,007 |
|
|
$ |
2,721 |
|
|
$ |
(22,943 |
) |
|
$ |
13,785 |
|
|
Other income (expense), net |
|
|
(564 |
) |
|
|
(1,486 |
) |
|
|
1,319 |
|
|
|
(731 |
) |
|
Depreciation and amortization |
|
|
4,039 |
|
|
|
2,581 |
|
|
|
1,930 |
|
|
|
8,550 |
|
|
Amortization of acquired intangibles |
|
|
373 |
|
|
|
— |
|
|
|
— |
|
|
|
373 |
|
|
EBITDA |
|
$ |
37,855 |
|
|
$ |
3,816 |
|
|
$ |
(19,694 |
) |
|
$ |
21,977 |
|
|
Share-based compensation |
|
|
3,236 |
|
|
|
1,120 |
|
|
|
4,775 |
|
|
|
9,131 |
|
|
Foreign exchange impact |
|
|
433 |
|
|
|
1,485 |
|
|
|
261 |
|
|
|
2,179 |
|
|
Strategic investments |
|
|
812 |
|
|
|
— |
|
|
|
7,054 |
|
|
|
7,866 |
|
|
Acquisition-related fair value adjustments |
|
|
1,473 |
|
|
|
— |
|
|
|
— |
|
|
|
1,473 |
|
|
Gain on investment securities |
|
|
— |
|
|
|
— |
|
|
|
(1,399 |
) |
|
|
(1,399 |
) |
|
Legal judgments/settlements |
|
|
179 |
|
|
|
294 |
|
|
|
48 |
|
|
|
521 |
|
|
Succession charges |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
Adjusted EBITDA |
|
$ |
43,988 |
|
|
$ |
6,715 |
|
|
$ |
(8,955 |
) |
|
$ |
41,748 |
|
Adjusted Net Income
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
||||||||||
|
(Unaudited, U.S. Dollars, in thousands) |
|
2019 |
|
|
2018 |
|
|
2019 |
|
|
2018 |
|
||||
|
Net income (loss) |
|
$ |
(547 |
) |
|
$ |
925 |
|
|
$ |
350 |
|
|
$ |
6,151 |
|
|
Foreign exchange impact |
|
|
(283 |
) |
|
|
3,255 |
|
|
|
590 |
|
|
|
2,179 |
|
|
Strategic investments |
|
|
4,825 |
|
|
|
4,651 |
|
|
|
6,894 |
|
|
|
7,868 |
|
|
Acquisition-related fair value adjustments |
|
|
647 |
|
|
|
1,473 |
|
|
|
6,579 |
|
|
|
1,473 |
|
|
Amortization of acquired intangibles |
|
|
1,338 |
|
|
|
310 |
|
|
|
2,395 |
|
|
|
373 |
|
|
Interest and (gain) loss on investment securities |
|
|
(96 |
) |
|
|
230 |
|
|
|
(689 |
) |
|
|
(1,399 |
) |
|
Legal judgments/settlements |
|
|
(877 |
) |
|
|
374 |
|
|
|
(752 |
) |
|
|
521 |
|
|
Succession charges |
|
|
1,268 |
|
|
|
— |
|
|
|
4,000 |
|
|
|
— |
|
|
Long-term income tax rate adjustment |
|
|
(804 |
) |
|
|
(3,213 |
) |
|
|
(8,723 |
) |
|
|
(1,803 |
) |
|
Adjusted net income |
|
$ |
5,471 |
|
|
$ |
8,005 |
|
|
$ |
10,644 |
|
|
$ |
15,363 |
|
Adjusted EPS
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
||||||||||
|
(Unaudited, per diluted share) |
|
2019 |
|
|
2018 |
|
|
2019 |
|
|
2018 |
|
||||
|
EPS |
|
$ |
(0.03 |
) |
|
$ |
0.05 |
|
|
$ |
0.02 |
|
|
$ |
0.32 |
|
|
Foreign exchange impact |
|
|
(0.01 |
) |
|
|
0.17 |
|
|
|
0.03 |
|
|
|
0.12 |
|
|
Strategic investments |
|
|
0.25 |
|
|
|
0.24 |
|
|
|
0.36 |
|
|
|
0.41 |
|
|
Acquisition-related fair value adjustments |
|
|
0.03 |
|
|
|
0.08 |
|
|
|
0.34 |
|
|
|
0.08 |
|
|
Amortization of acquired intangibles |
|
|
0.07 |
|
|
|
0.02 |
|
|
|
0.12 |
|
|
|
0.02 |
|
|
Interest and (gain) loss on investment securities |
|
|
— |
|
|
|
0.01 |
|
|
|
(0.04 |
) |
|
|
(0.07 |
) |
|
Legal judgments/settlements |
|
|
(0.05 |
) |
|
|
0.02 |
|
|
|
(0.04 |
) |
|
|
0.03 |
|
|
Succession charges |
|
|
0.07 |
|
|
|
— |
|
|
|
0.21 |
|
|
|
— |
|
|
Long-term income tax rate adjustment |
|
|
(0.05 |
) |
|
|
(0.17 |
) |
|
|
(0.45 |
) |
|
|
(0.10 |
) |
|
Adjusted EPS |
|
$ |
0.28 |
|
|
$ |
0.42 |
|
|
$ |
0.55 |
|
|
$ |
0.81 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of diluted common shares (treasury stock method) |
|
|
19,272,139 |
|
|
|
18,980,808 |
|
|
|
19,280,140 |
|
|
|
18,945,356 |
|
Free Cash Flow
|
|
|
Six Months Ended June 30, |
|
|||||
|
(Unaudited, U.S. Dollars, in thousands) |
|
2019 |
|
|
2018 |
|
||
|
Net cash from operating activities |
|
$ |
8,344 |
|
|
$ |
13,032 |
|
|
Capital expenditures |
|
|
(10,338 |
) |
|
|
(6,652 |
) |
|
Free cash flow |
|
$ |
(1,994 |
) |
|
$ |
6,380 |
|
2019 Outlook
|
|
|
Previous 2019 Outlook |
|
|
Current 2019 Outlook |
|
||||||||||
|
(Unaudited, U.S. Dollars, in millions) |
|
Low |
|
|
High |
|
|
Low |
|
|
High |
|
||||
|
Net income |
|
$ |
14.6 |
|
|
$ |
15.5 |
|
|
$ |
12.7 |
|
|
$ |
13.6 |
|
|
Interest expense, net |
|
|
0.8 |
|
|
|
0.9 |
|
|
|
(1.2 |
) |
|
|
(1.2 |
) |
|
Income tax expense |
|
|
5.9 |
|
|
|
6.4 |
|
|
|
6.8 |
|
|
|
7.3 |
|
|
Depreciation and amortization |
|
|
24.2 |
|
|
|
24.2 |
|
|
|
24.5 |
|
|
|
24.6 |
|
|
EBITDA |
|
$ |
45.5 |
|
|
$ |
47.0 |
|
|
$ |
42.8 |
|
|
$ |
44.3 |
|
|
Share-based compensation |
|
|
19.1 |
|
|
|
20.1 |
|
|
|
19.3 |
|
|
|
20.4 |
|
|
Foreign exchange impact |
|
|
0.9 |
|
|
|
0.9 |
|
|
|
0.6 |
|
|
|
0.6 |
|
|
Strategic investments |
|
|
4.8 |
|
|
|
4.9 |
|
|
|
8.7 |
|
|
|
8.9 |
|
|
Acquisition-related fair value adjustments |
|
|
8.5 |
|
|
|
8.7 |
|
|
|
7.7 |
|
|
|
7.7 |
|
|
Interest and (gain) loss on investment securities |
|
|
(0.5 |
) |
|
|
(0.5 |
) |
|
|
— |
|
|
|
— |
|
|
Legal judgments/settlements |
|
|
1.3 |
|
|
|
1.3 |
|
|
|
(0.5 |
) |
|
|
(0.5 |
) |
|
Succession charges |
|
|
6.4 |
|
|
|
6.6 |
|
|
|
7.4 |
|
|
|
7.6 |
|
|
Adjusted EBITDA |
|
$ |
86.0 |
|
|
$ |
89.0 |
|
|
$ |
86.0 |
|
|
$ |
89.0 |
|
|
|
|
Previous 2019 Outlook |
|
|
Current 2019 Outlook |
|
||||||||||
|
(Unaudited, per diluted share) |
|
Low |
|
|
High |
|
|
Low |
|
|
High |
|
||||
|
EPS |
|
$ |
0.75 |
|
|
$ |
0.80 |
|
|
$ |
0.66 |
|
|
$ |
0.70 |
|
|
Foreign exchange impact |
|
|
0.05 |
|
|
|
0.05 |
|
|
|
0.03 |
|
|
|
0.03 |
|
|
Strategic investments |
|
|
0.25 |
|
|
|
0.25 |
|
|
|
0.45 |
|
|
|
0.46 |
|
|
Acquisition-related fair value adjustments |
|
|
0.44 |
|
|
|
0.45 |
|
|
|
0.40 |
|
|
|
0.40 |
|
|
Amortization of intangible assets |
|
|
0.25 |
|
|
|
0.25 |
|
|
|
0.25 |
|
|
|
0.26 |
|
|
Interest and (gain) loss on investment securities |
|
|
(0.03 |
) |
|
|
(0.03 |
) |
|
|
(0.09 |
) |
|
|
(0.09 |
) |
|
Legal judgments/settlements |
|
|
0.07 |
|
|
|
0.07 |
|
|
|
(0.02 |
) |
|
|
(0.02 |
) |
|
Succession charges |
|
|
0.33 |
|
|
|
0.34 |
|
|
|
0.38 |
|
|
|
0.39 |
|
|
Long-term income tax rate adjustment |
|
|
(0.36 |
) |
|
|
(0.36 |
) |
|
|
(0.31 |
) |
|
|
(0.31 |
) |
|
Adjusted EPS |
|
$ |
1.75 |
|
|
$ |
1.82 |
|
|
$ |
1.75 |
|
|
$ |
1.82 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of diluted common shares (treasury stock method) |
|
|
19,375,000 |
|
|
|
19,375,000 |
|
|
|
19,375,000 |
|
|
|
19,375,000 |
|
Constant Currency
Constant currency is a non-GAAP measure, which is calculated by using foreign currency rates from the comparable, prior-year period, to present net sales at comparable rates. Constant currency can be presented for numerous GAAP measures, but is most commonly used by management to analyze net sales without the impact of changes in foreign currency rates.
EBITDA
EBITDA is a non-GAAP financial measure, which is calculated by adding interest expense, net; income tax expense; and depreciation and amortization to net income. EBITDA provides management with additional insight to its results of operations. EBITDA is the primary metric used by our Chief Operating Decision Maker in managing our business.
Adjusted EBITDA, Adjusted Net Income and Adjusted EPS
These non-GAAP financial measures provide management with additional insight to its results of operations and are calculated using the following adjustments:
- Share-based compensation – costs related to our share-based compensation plans, which include stock options, restricted stock awards, performance-based restricted stock awards, market-based restricted stock awards and our stock purchase plan; see the share-based compensation footnote in our Form 10-Q for the quarter ended June 30, 2019 for a detail of these costs by consolidated statement of income line item; however, certain share-based compensation costs have been included within succession charges for 2019
- Foreign exchange impact – gains and losses related to foreign currency transactions, which are recorded as other expense, net; guidance presented does not include the impact of any future foreign exchange fluctuations
-
Strategic investments – costs related to our strategic investments, such as due diligence and integration costs, or costs associated with the evaluation and completion of changing the Company’s jurisdiction of organization from Curaçao to the State of Delaware during 2018, which are primarily recorded as general and administrative expenses.
Amounts previously reported as “Domestication to Delaware” have been reclassified to this line item to conform to current period presentation, resulting in an increase in strategic investments of $1.9 million for the three months ended June 30, 2018; an increase of $2.7 million for the six months ended June 30, 2018; and an increase of $0.1 million for the six months ended June 30, 2019
- Acquisition-related fair value adjustments – comprised of i) gains and losses related to remeasurement of contingent consideration to fair value, which are recorded as operating expenses, and ii) the amortization of an adjustment made to inventory acquired to reflect the expected selling price of the acquired inventory less the cost of expected selling efforts and a reasonable profit allowance for the selling effort for finished goods inventory, which is recorded as cost of sales
- Amortization of acquired intangibles – amortization of intangible assets acquired in business combinations or asset acquisitions, including items such as developed technologies, in process research and development, trade names, and other intangible assets, which are recorded as operating expenses
- Interest and (gain) loss on investment securities – net gains or losses recognized within other expense, net, or amortization of historical unrealized gains previously recorded within accumulated other comprehensive income to interest income relating to our investments in eNeura Inc. and Bone Biologics, Inc.
- Legal judgments/settlements – adverse or favorable legal judgments or negotiated legal settlements, including legal and other professional fees associated with the SEC Investigation, Securities Class Action Complaints and Brazil subsidiary compliance review, which are typically recorded as general and administrative expenses
- Succession charges – costs related to the transition of the Company’s named executive officers, including any cessation and onboarding amounts, accelerated share-based compensation expense, consulting services and other related expenses
- Long-term income tax rate adjustment – reflects management’s expectation of a long-term normalized effective tax rate of 35% for the first and second quarters of 2018, 29% for the third and fourth quarters of 2018, and 27% for our 2019 results and outlook, which is based on current tax law and current expected income; actual reported tax expense will ultimately be based on GAAP earnings and may differ from the expected long-term normalized effective tax rate due to a variety of factors, including the resolutions of issues arising from tax audits with various tax authorities, the ability to realize deferred tax assets, and the tax impact of certain reconciling items that are excluded in determining Adjusted Net Income
Free Cash Flow
Free cash flow is a non-GAAP financial measure, which is calculated by subtracting capital expenditures from cash flow from operating activities. Free cash flow is an important indicator of how much cash is generated or used by our normal business operations, including capital expenditures.
Contacts
Orthofix Medical Inc.
Mark Quick
P: 214-937-2924
E: markquick@orthofix.com